You are on in-line skates at the top of a small hill. Your potential energy is equal to 1,000 J. The last time you checked your mass was 60.0 kg. A. What is the height of the hill.

B. If you start rolling down this hill, your potential energy will be converted into kinetic energy. At the bottom of the hill, your kinetic energy will be equal to your potential energy at the top. Calculate your speed at the bottom of the hill.

If vx = 7.00 units and vy = -7.60 units, determine the magnitude of v⃗ . determine the direction of v⃗ .

Use the frequency histogram to complete the following parts. ​(a) identify the class with the​ greatest, and the class with the​ least, relative frequency. ​(b) estimate the greatest and least relative frequencies. ​(c) describe any patterns with the data. female fibula lengths 30.5 31.5 32.5 33.5 34.5 35.5 36.5 37.5 38.5 39.5 0 0.05 0.1 0.15 0.2 0.25 length (in centimeters) relative frequency a histogram titled "female fibula lengths" has a horizontal axis labeled "length in centimeters" from 30.5 to 39.5 in increments of 1 and a vertical axis labeled "relative frequency" from 0 to 0.25 in increments of 0.05. the histogram contains vertical bars of width 1, where one vertical bar is centered over each of the horizontal axis tick marks. the approximate heights of the vertical bars are listed as follows, where the label is listed first and the approximate height is listed second: 30.5, 0.02; 31.5, 0.04; 32.5, 0.05; 33.5, 0.13; 34.5, 0.22; 35.5, 0.25; 36.5, 0.13; 37.5, 0.06; 38.5, 0.09; 39.5, 0.01. ​(a) the class with the greatest relative frequency is nothing to nothing centimeters. ​(type integers or decimals. do not round. use ascending​ order.)

Asubject in a clinical research trial experiences a serious, unanticipated adverse drug experience. how should the investigator proceed, with respect to the irb, after the discovery of the adverse event occurrence? a. do not report the adverse drug experience to the irb since it is a common adverse experience. b. report the adverse drug experience to the irb only if there are several other occurrences. c. report the adverse drug experience as part of the continuing review report. d. report the adverse drug experience in a timely manner, in keeping with the irb's policies and procedures, using the forms or the mechanism provided by the irb.